Compass Therapeutics’ Chief Accounting Officer Buys 2,500 Shares Amid 70% Stock Slide and Pending FDA Trial Approval
Compass Therapeutics insider buying signals confidence amid volatile market; COO’s recent share purchase highlights trust in FDA milestones and long‑term value.
3 minutes to read